INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
USA - NASDAQ:IART - US4579852082 - Common Stock
11.75 USD
-0.29 (-2.41%)
11.75 USD
0 (0%)
Overall IART gets a fundamental rating of 4 out of 10. We evaluated IART against 188 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
IART had positive earnings in 4 of the past 5 years.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART's Return On Assets of -13.58% is in line compared to the rest of the industry. IART outperforms 56.08% of its industry peers.
IART's Return On Equity of -47.74% is in line compared to the rest of the industry. IART outperforms 51.32% of its industry peers.
The Return On Invested Capital of IART (4.27%) is better than 74.07% of its industry peers.
IART had an Average Return On Invested Capital over the past 3 years of 6.10%. This is below the industry average of 8.98%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART's Operating Margin of 10.22% is fine compared to the rest of the industry. IART outperforms 77.25% of its industry peers.
IART's Operating Margin has declined in the last couple of years.
IART has a Gross Margin of 57.21%. This is comparable to the rest of the industry: IART outperforms 56.08% of its industry peers.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
IART has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for IART has been reduced compared to 1 year ago.
IART has less shares outstanding than it did 5 years ago.
IART has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.23, we must say that IART is in the distress zone and has some risk of bankruptcy.
IART has a Altman-Z score (1.23) which is comparable to the rest of the industry.
IART has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
IART has a Debt to Equity ratio of 1.73. This is amonst the worse of the industry: IART underperforms 81.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.23 |
ROIC/WACC0.82
WACC5.23%
2.3 Liquidity
A Current Ratio of 3.14 indicates that IART has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.14, IART is in the better half of the industry, outperforming 61.38% of the companies in the same industry.
A Quick Ratio of 1.80 indicates that IART should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.80, IART is in line with its industry, outperforming 47.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The earnings per share for IART have decreased by -4.44% in the last year.
The Earnings Per Share has been decreasing by -1.35% on average over the past years.
Looking at the last year, IART shows a small growth in Revenue. The Revenue has grown by 4.99% in the last year.
IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.20% yearly.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
The Earnings Per Share is expected to grow by 2.68% on average over the next years.
Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 2.39% on average per year.
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IART is valuated cheaply with a Price/Earnings ratio of 4.96.
96.83% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.89.
The Price/Forward Earnings ratio is 4.86, which indicates a rather cheap valuation of IART.
IART's Price/Forward Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 98.94% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of IART to the average of the S&P500 Index (34.59), we can say IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.96 | ||
| Fwd PE | 4.86 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaper than 94.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.66 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.75
-0.29 (-2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.73%
Inst Owner Change0.01%
Ins Owners3.04%
Ins Owner Change0.07%
Market Cap915.44M
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target17.34 (47.57%)
Short Float %10%
Short Ratio6.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)3.48%
PT rev (3m)3.48%
EPS NQ rev (1m)-11.49%
EPS NQ rev (3m)-11.49%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)-5.75%
Revenue NQ rev (3m)-5.75%
Revenue NY rev (1m)-2.11%
Revenue NY rev (3m)-1.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.96 | ||
| Fwd PE | 4.86 | ||
| P/S | 0.56 | ||
| P/FCF | N/A | ||
| P/OCF | 10.25 | ||
| P/B | 0.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.66 |
EPS(TTM)2.37
EY20.17%
EPS(NY)2.42
Fwd EY20.58%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY9.76%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.23 |
F-Score5
WACC5.23%
ROIC/WACC0.82
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.98%
EBIT Next 3Y9.96%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.